Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01010061 · OUTCOME

Overall Survival

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) · Source last updated 2018-09-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

What was measured

Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.

Analysis population: Intent-to-treat population included all randomized participants. Patients without OS events were censored.

Groups in this outcome

Obinutuzumab + Chlorambucil (GClb)

Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).

Chlorambucil (Clb)

Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Obinutuzumab + Chlorambucil (GClb)238
Chlorambucil (Clb)118

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Obinutuzumab + Chlorambucil (GClb)NANot reported74.2NAThe median survival time and upper limit of 95% CI could not be estimated due to a low number of deaths.
Chlorambucil (Clb)66.7Not reported50.9NAThe upper limit of 95% CI could not be estimated due to a low number of deaths.

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.49
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.94
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.0196
    param Type
    Hazard Ratio (HR)
    param Value
    0.68
    statistical Method
    Log Rank, Stratified
Complete source fields
analyses
  1. ci Lower Limit
    0.49
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.94
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.0196
    param Type
    Hazard Ratio (HR)
    param Value
    0.68
    statistical Method
    Log Rank, Stratified
classes
  1. categories
    1. measurements
      1. comment
        The median survival time and upper limit of 95% CI could not be estimated due to a low number of deaths.
        group Id
        OG000
        lower Limit
        74.2
        upper Limit
        NA
        value
        NA
      2. comment
        The upper limit of 95% CI could not be estimated due to a low number of deaths.
        group Id
        OG001
        lower Limit
        50.9
        upper Limit
        NA
        value
        66.7
denoms
  1. counts
    1. group Id
      OG000
      value
      238
    2. group Id
      OG001
      value
      118
    units
    Participants
description
Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
    id
    OG000
    title
    Obinutuzumab + Chlorambucil (GClb)
  2. description
    Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
    id
    OG001
    title
    Chlorambucil (Clb)
param Type
MEDIAN
population Description
Intent-to-treat population included all randomized participants. Patients without OS events were censored.
reporting Status
POSTED
time Frame
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice